Abstract
Adiponectin, a secretory protein specifically expressed by adipose tissue, has been shown to play a critical role in the maintenance of metabolic homeostasis. A deficiency of adiponectin has been linked to a wide variety of metabolic abnormalities, including obesity and associated disorders such as insulin resistance, hyperglycemia, dyslipidemia, hypertension and nonalcoholic fatty liver disease, collectively referred to as the “metabolic syndrome”. Conversely, increased expression of adiponectin corrects these abnormalities, as revealed by the positive metabolic effects observed in genetic over expression studies or by administration of recombinant adiponectin. This has led to widespread interest in its role as a therapeutic target for treatment of a range of metabolic disorders such as diabetes mellitus, obesity, inflammatory and cardiovascular diseases. Various therapeutic approaches targeted at increasing adiponectin levels, or its activity, are being explored. These consist of increasing expression of adiponectin or its receptors by inducers, increasing circulating levels of adiponectin by administering recombinant protein, peptide mimetic approaches, or increasing expression/activity of its downstream effectors such as AMPK or PPAR alpha. Many of these approaches have achieved therapeutic benefits in animal models of metabolic diseases. Despite the profusion of research on adiponectin and ways to modulate it, there are limited number of studies focused on smallmolecule based-therapeutic approaches. In this review, we summarize what is currently known with respect to the therapeutic potential of adiponectin and discuss the challenges in designing small molecule-based therapies.
Keywords: Adiponectin, metabolic syndrome, diabetes, obesity, cardiovascular, mitochondria, AMPK, PPAR.
Current Pharmaceutical Design
Title:Role of Adiponectin in the Metabolic Syndrome: Current Perspectives on its Modulation as a Treatment Strategy
Volume: 19 Issue: 32
Author(s): Indira Padmalayam and Mark Suto
Affiliation:
Keywords: Adiponectin, metabolic syndrome, diabetes, obesity, cardiovascular, mitochondria, AMPK, PPAR.
Abstract: Adiponectin, a secretory protein specifically expressed by adipose tissue, has been shown to play a critical role in the maintenance of metabolic homeostasis. A deficiency of adiponectin has been linked to a wide variety of metabolic abnormalities, including obesity and associated disorders such as insulin resistance, hyperglycemia, dyslipidemia, hypertension and nonalcoholic fatty liver disease, collectively referred to as the “metabolic syndrome”. Conversely, increased expression of adiponectin corrects these abnormalities, as revealed by the positive metabolic effects observed in genetic over expression studies or by administration of recombinant adiponectin. This has led to widespread interest in its role as a therapeutic target for treatment of a range of metabolic disorders such as diabetes mellitus, obesity, inflammatory and cardiovascular diseases. Various therapeutic approaches targeted at increasing adiponectin levels, or its activity, are being explored. These consist of increasing expression of adiponectin or its receptors by inducers, increasing circulating levels of adiponectin by administering recombinant protein, peptide mimetic approaches, or increasing expression/activity of its downstream effectors such as AMPK or PPAR alpha. Many of these approaches have achieved therapeutic benefits in animal models of metabolic diseases. Despite the profusion of research on adiponectin and ways to modulate it, there are limited number of studies focused on smallmolecule based-therapeutic approaches. In this review, we summarize what is currently known with respect to the therapeutic potential of adiponectin and discuss the challenges in designing small molecule-based therapies.
Export Options
About this article
Cite this article as:
Padmalayam Indira and Suto Mark, Role of Adiponectin in the Metabolic Syndrome: Current Perspectives on its Modulation as a Treatment Strategy, Current Pharmaceutical Design 2013; 19 (32) . https://dx.doi.org/10.2174/13816128113199990360
DOI https://dx.doi.org/10.2174/13816128113199990360 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
"Tuberculosis Prevention, Diagnosis and Drug Discovery"
The Nobel Prize-winning discoveries of Mycobacterium tuberculosis and streptomycin have enabled an appropriate diagnosis and an effective treatment of tuberculosis (TB). Since then, many newer diagnosis methods and drugs have been saving millions of lives. Despite advances in the past, TB is still a leading cause of infectious disease mortality ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Emerging and re-emerging diseases
Faced with a possible endemic situation of COVID-19, the world has experienced two important phenomena, the emergence of new infectious diseases and/or the resurgence of previously eradicated infectious diseases. Furthermore, the geographic distribution of such diseases has also undergone changes. This context, in turn, may have a strong relationship with ...read more
Melanoma and Non-Melanoma Skin Cancer Treatment: Standard of Care and Recent Advances
In this thematic issue, we aim to provide a standard of care of the diagnosis and treatment of melanoma and non-melanoma skin cancer. The editor will invite authors from different countries who will write review articles of melanoma and non-melanoma skin cancers. The Diagnosis, Staging, Surgical Treatment, Non-Surgical Treatment all ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Inhibitors of Apoptosis Proteins (IAPs) as Potential Molecular Targets for Therapy of Hematological Malignancies
Current Molecular Medicine 3D-QSAR Studies on a Series of 5-Arylidine-2, 4-Thiazolidinediones as Aldose Reductase Inhibitors: A Self-Organizing Molecular Field Analysis Approach
Medicinal Chemistry Patent Annotations
Recent Patents on CNS Drug Discovery (Discontinued) Nutritional Overview on the Management of Type 2 Diabetes and the Prevention of its Complications
Current Diabetes Reviews Methylglyoxal and Advanced Glycation Endproducts: New Therapeutic Horizons?
Recent Patents on Cardiovascular Drug Discovery From Endothelial Dysfunction to Arterial Stiffness in Diabetes Mellitus
Current Diabetes Reviews Perspectives on Medicinal Properties of Benzoquinone Compounds
Mini-Reviews in Medicinal Chemistry Microcirculation of the Diabetic Foot
Current Pharmaceutical Design Neuropathic Pain and Lung Delivery of Nanoparticulate Drugs: An Emerging Novel Therapeutic Strategy
CNS & Neurological Disorders - Drug Targets Metabolic Control of Type 2 Diabetes by Targeting the GLUT4 Glucose Transporter: Intervention Approaches
Current Pharmaceutical Design A New Alzheimers Disease Interventive Strategy: GLP-1
Current Drug Targets Advances in Mycobacterial Isocitrate Lyase Targeting and Inhibitors
Current Medicinal Chemistry Mitochondrial DNA Mutations in Cancer: A Review
Current Topics in Medicinal Chemistry Application of Hydrogen in Ophthalmology
Current Pharmaceutical Design Bioengineered Polymer/Composites as Advanced Biological Detection of Sorbitol: An Application in Healthcare Sector
Current Topics in Medicinal Chemistry Monoclonal Antibodies: A Target Therapy for Multiple Sclerosis
Inflammation & Allergy - Drug Targets (Discontinued) Opioids and Cannabinoids Interactions: Involvement in Pain Management
Current Drug Targets Inhibitors and Breakers of Advanced Glycation Endproducts (AGEs): A Review
Current Medicinal Chemistry - Immunology, Endocrine & Metabolic Agents Advances in the Development of Bradykinin Receptor Ligands
Current Topics in Medicinal Chemistry Diabetes, the Renin-Angiotensin System and Heart Disease
Current Vascular Pharmacology